Form 8-K - Current report:
SEC Accession No. 0001034842-26-000043
Filing Date
2026-06-17
Accepted
2026-06-17 16:05:28
Documents
11
Period of Report
2026-06-11
Items
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 8-K rigl-20260611.htm   iXBRL 8-K 20797
  Complete submission text file 0001034842-26-000043.txt   138008

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rigl-20260611.xsd EX-101.SCH 1764
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rigl-20260611_lab.xml EX-101.LAB 22804
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rigl-20260611_pre.xml EX-101.PRE 13034
14 EXTRACTED XBRL INSTANCE DOCUMENT rigl-20260611_htm.xml XML 2835
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 261098342
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)